Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells.

Stover T, Kester M.

J Pharmacol Exp Ther. 2003 Nov;307(2):468-75. Epub 2003 Sep 15.

2.

Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.

Stover TC, Sharma A, Robertson GP, Kester M.

Clin Cancer Res. 2005 May 1;11(9):3465-74.

3.

Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug.

Stover TC, Kim YS, Lowe TL, Kester M.

Biomaterials. 2008 Jan;29(3):359-69. Epub 2007 Oct 26.

PMID:
17964645
4.
5.

Taxol-induced ceramide generation and apoptosis in human breast cancer cells.

Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, Cabot MC.

Cancer Chemother Pharmacol. 2001 May;47(5):444-50.

PMID:
11391861
6.

Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.

Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur AB.

Int J Pharm. 2007 Aug 16;341(1-2):221-9. Epub 2007 Apr 3.

PMID:
17499461
7.

Apoptosis induced by intracellular ceramide accumulation in MDA-MB-435 breast carcinoma cells is dependent on the generation of reactive oxygen species.

Chan SY, Hilchie AL, Brown MG, Anderson R, Hoskin DW.

Exp Mol Pathol. 2007 Feb;82(1):1-11. Epub 2006 Apr 19.

PMID:
16624283
8.

Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.

Tran MA, Smith CD, Kester M, Robertson GP.

Clin Cancer Res. 2008 Jun 1;14(11):3571-81. doi: 10.1158/1078-0432.CCR-07-4881.

9.

Rapid distribution of liposomal short-chain ceramide in vitro and in vivo.

Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, McNeil SE.

Drug Metab Dispos. 2008 Aug;36(8):1709-15. doi: 10.1124/dmd.107.019679. Epub 2008 May 19.

10.

PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery.

Zou P, Stern ST, Sun D.

Pharm Res. 2014 Mar;31(3):684-93. doi: 10.1007/s11095-013-1190-5. Epub 2013 Sep 25.

11.

Novel ceramide analogs as potential chemotherapeutic agents in breast cancer.

Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS.

J Pharmacol Exp Ther. 2004 May;309(2):523-32. Epub 2004 Jan 23.

12.

Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.

Fonseca NA, Gomes-da-Silva LC, Moura V, Simões S, Moreira JN.

J Control Release. 2014 Dec 28;196:122-31. doi: 10.1016/j.jconrel.2014.09.024. Epub 2014 Oct 11.

PMID:
25305563
13.

In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.

Chintalapati M, Truax R, Stout R, Portier R, Losso JN.

J Agric Food Chem. 2009 Jun 24;57(12):5201-10. doi: 10.1021/jf803818y.

PMID:
19476359
14.

Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.

Shabbits JA, Mayer LD.

Biochim Biophys Acta. 2003 May 2;1612(1):98-106.

15.

beta-Sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism.

Awad AB, Barta SL, Fink CS, Bradford PG.

Mol Nutr Food Res. 2008 Apr;52(4):419-26. doi: 10.1002/mnfr.200700222.

PMID:
18338406
16.

High ceramide content liposomes with in vivo antitumor activity.

Shabbits JA, Mayer LD.

Anticancer Res. 2003 Sep-Oct;23(5A):3663-9.

PMID:
14666662
18.

Development and use of ceramide nanoliposomes in cancer.

Watters RJ, Kester M, Tran MA, Loughran TP Jr, Liu X.

Methods Enzymol. 2012;508:89-108. doi: 10.1016/B978-0-12-391860-4.00005-7.

PMID:
22449922
19.

Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M.

Clin Cancer Res. 2003 Oct 1;9(12):4595-605.

Supplemental Content

Support Center